Sorin: Many growth opportunities despite challenging markets

BUY, Fair Value EUR2.4 (+18%)

News published on November Thursday 28, 2013
Share on

Sorin yesterday held an Investors Day in Milan at which the company detailed several growth drivers such as HeartLink/Connect/Inspire in Cardiac Surgery, SonR in Cardiac Rythym Management as well as the New Ventures projects. Emerging countries which represent currently 15% of sales are set to represent 25% of sales in 2018. At a group level, Sorin guides on a 3-5% topline growth in 2013-2016 and 8-10% in 2016-2018 including the contribution of the New Ventures. Regarding EPS, the 5-year target is to reach >EUR0.20 in the base business. Despite challenging underlying effects as well as an unfavourable FX environment (c.EUR10m expected in bottom line in 2014), we continue to like Sorin for its long-term perspectives on the base business and new ventures as well as management's track record on execution.

Full report available to subscribers
Please contact   

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities